NCT07903701
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Secondary endpoints: 2 to 8
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at Day 90
Timeframe: Day 90
Secondary (8)
mRS distribution at Day 30 and 90;
Proportions of symptomatic intracranial hemorrhage within 36 h, intracranial hemorrhage, and major extracranial hemorrhage 90-day mortality
Number of Participants With Any Adverse Event (AE)
Number of Participants With Treatment-Related Adverse Events (TRAEs)
Number of Participants With Serious Adverse Events (SAEs)
Show 3 moreShow less
Number of Participants With Clinically Significant Abnormal Laboratory Values
Number of Participants With Clinically Significant Abnormal Vital Signs
Number of Participants With Clinically Significant Abnormal Physical Examination Findings
Arms and interventions
SIM0811 2 Dose Level A (Phase II)Experimental
Participants receive SIM0811 Dose Level A.
SIM0811 Dose Level B (Phase II)Experimental
Participants receive SIM0811 Dose Level B.
SIM0811Dose Level C (Phase II)Experimental
Participants receive SIM0811 Dose Level C.
Placebo(Phase II)Placebo comparator
Participants receive SIM0811 placebo.
SIM0811(Phase III)Experimental
Participants receive the selected target dose of SIM0811.
Placebo (Phase III)Placebo comparator
Participants receive SIM0811 placebo.
Drugs: SIM0811 Dose Level A (Phase II), SIM0811 Dose Level B (Phase II), SIM0811 Dose Level C (Phase II), Placebo(Phase II), SIM0811(Phase III), Placebo(Phase III)